GS-0201 + sacituzumab govitecan

GS-0201 + sacituzumab govitecan is an investigational combination therapy currently in Phase 1 trials for the treatment of advanced solid tumors. GS-0201 is a small molecule inhibitor targeting Poly (ADP-Ribose) polymerase 1 (PARP1), a key enzyme in DNA damage repair mechanisms, offering a targeted therapy approach for solid tumors[3][5]. Sacituzumab govitecan is an antibody-drug conjugate (ADC) consisting of a humanized monoclonal antibody against TROP-2 linked to SN-38, an active metabolite of irinotecan which inhibits DNA topoisomerase I and induces selective cell death in tumors expressing TROP-2[2][7]. This combination is designed to leverage dual mechanisms—PARP inhibition and targeted cytotoxic delivery—to improve antineoplastic efficacy in difficult-to-treat cancers[1][7]. GS-0201 is developed by Gilead Sciences and sacituzumab govitecan (Trodelvy) by Immunomedics, now a subsidiary of Gilead Sciences[2][5]. Primary indications include advanced malignant solid neoplasms, including metastatic breast cancer and other solid tumors[1][3][7].

Other names

sacituzumab govitecan-hziyRS7-SN38RS-7-SN38RS 7-SN38